Trials / Unknown
UnknownNCT05334576
Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA
Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA Novartis Investigator Initiated Trial: CSEG101AUS12T
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 31 (estimated)
- Sponsor
- Andria Ford · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
In this prospective, single-arm, open-label, imaging and treatment study, the investigator will test the hypothesis that crizanlizumab will prevent the progression of silent cerebral infarcts in patients with sickle cell disease. Study participants will undergo brain MRI before initiation of crizanlizumab and at 6 and 30 months after starting crizanlizumab infusions. The crizanlizumab cohort will be compared to a matched, observational cohort of patients not receiving crizanlizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Crizanlizumab | Crizanlizumab 5.0 mg/kg infusions will be administered over 24 months |
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2024-07-01
- Completion
- 2025-07-01
- First posted
- 2022-04-19
- Last updated
- 2023-03-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05334576. Inclusion in this directory is not an endorsement.